Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
Status and phase
Completed
Phase 1
Conditions
Healthy
Treatments
Drug: AZD2066
Drug: radioligand [11C] AZ12713580
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace [11C]AZ12713580 from mGluR5 binding-sites in the Central Nervous System
Enrollment
6 estimated patients
Sex
All
Ages
20 to 45 years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Provision of informed consent
- BMI (Body Mass Index) of ≥19 to ≤28 kg/m2 and weight of ≥50 to ≤100 kg
- Normal MRI (Magnetic Resonance Imaging) scan at visit 2
Exclusion criteria
- History of previous or ongoing psychiatric disease or condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders
- History of psychotic disorder among first degree relatives (parents, siblings)
- History of use of antipsychotic, antidepressant or anxiolytic (anxiety treatment) drugs, prescribed or non-prescribed use. History of antidepressants or anxiolytics for non-psychiatric conditions such as pain or post-operative insomnia is allowed
Trial design
Primary purpose
Basic Science
Allocation
Non-Randomized
Interventional model
Single Group Assignment
Masking
None (Open label)
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems